Organisation paid for research Program year 2025 Source: CMS Open Payments

GCP Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$7,762,613

869 payments

Through program year 2025, GCP Clinical Research LLC is reported as receiving $7,762,613 in research payments, across 869 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,150,340 239
2024 Research $1,338,418 179
2023 Research $923,039 157
2022 Research $404,144 78
2021 Research $362,907 46
2020 Research $243,801 32
2019 Research $339,965 138

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $2,993,124 8 payments
  2. AbbVie, Inc. $1,942,591 399 payments
  3. Pfizer Inc. $868,044 273 payments
  4. Sanofi US Services Inc. $635,213 15 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $520,337 80 payments
  6. Arena Pharmaceuticals, Inc. $312,395 44 payments
  7. Eli Lilly and Company $212,798 4 payments
  8. Janssen Research & Development, LLC $185,493 31 payments
  9. Horizon Therapeutics plc $41,672 1 payment
  10. Sumitomo Pharma America, Inc. $40,447 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $2,245,090 1 payment
  2. P4 Uncontrolled Gout FORWARD $627,445 1 payment
  3. A Randomized Doubleblind Placebocontrolled 52Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis $607,128 162 payments
  4. A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet $593,280 9 payments
  5. A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet $487,737 69 payments
  6. M16-283 $392,963 143 payments
  7. Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis $265,794 22 payments
  8. A Multicenter Randomized Doubleblind Parallelgroup Study to Assess the Efficacy and Safety of Oral Etrasimod As Induction and Maintenance Therapy for Moderately to Severely Active Crohns Disease $251,067 66 payments
  9. A Multicenter, Phase 3B, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab $212,798 4 payments
  10. An Openlabel Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis $180,323 56 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record